Indication: 1 This product is used in combination with other anti-tuberculosis drugs for the initial and retreatment of various tuberculosis diseases, including the treatment of tuberculous meningitis. 2 This product is used in combination with other drugs to treat leprosy and non-tuberculous mycobacterial infections. 3 This product can be used in combination with vancomycin (intravenous) for severe infections caused by methicillin-resistant Staphylococci. The combination of rifampicin and erythromycin can be used for severe Legionella infections. 4 It is used for asymptomatic carriers of Neisseria meningitidis to eliminate Neisseria meningitidis in the nasopharynx; but it is not suitable for the treatment of Neisseria meningitidis infections.

Indication: 1 This product is used in combination with other anti-tuberculosis drugs for the initial and retreatment of various tuberculosis diseases, including the treatment of tuberculous meningitis. 2 This product is used in combination with other drugs to treat leprosy and non-tuberculous mycobacterial infections. 3 This product can be used in combination with vancomycin (intravenous) for severe infections caused by methicillin-resistant Staphylococci. The combination of rifampicin and erythromycin can be used for severe Legionella infections. 4 It is used for asymptomatic carriers of Neisseria meningitidis to eliminate Neisseria meningitidis in the nasopharynx; but it is not suitable for the treatment of Neisseria meningitidis infections.

Indication: 1 This product is used in combination with other anti-tuberculosis drugs for the initial and retreatment of various tuberculosis diseases, including the treatment of tuberculous meningitis. 2 This product is used in combination with other drugs to treat leprosy and non-tuberculous mycobacterial infections. 3 This product can be used in combination with vancomycin (intravenous) for severe infections caused by methicillin-resistant Staphylococci. The combination of rifampicin and erythromycin can be used for severe Legionella infections. 4 It is used for asymptomatic carriers of Neisseria meningitidis to eliminate Neisseria meningitidis in the nasopharynx; but it is not suitable for the treatment of Neisseria meningitidis infections.

Indication: 1. This product is used in combination with other anti-tuberculosis drugs for the initial and retreatment of various tuberculosis diseases, including the treatment of tuberculous meningitis. 2. This product is used in combination with other drugs for the treatment of leprosy and non-tuberculous mycobacterial infections. 3. This product can be used in combination with vancomycin (intravenous) for severe infections caused by methicillin-resistant Staphylococcus aureus. The combination of rifampicin and erythromycin can be used for severe Legionella infections. 4. It is used for asymptomatic carriers of Neisseria meningitidis to eliminate Neisseria meningitidis in the nasopharynx; but it is not suitable for the treatment of Neisseria meningitidis infections.

Indication: 1. This product is used in combination with other anti-tuberculosis drugs for the initial and retreatment of various tuberculosis diseases, including the treatment of tuberculous meningitis. 2. This product is used in combination with other drugs for the treatment of leprosy and non-tuberculous mycobacterial infections. 3. This product can be used in combination with vancomycin (intravenous) for severe infections caused by methicillin-resistant Staphylococcus aureus. The combination of rifampicin and erythromycin can be used for severe Legionella infections. 4. It is used for asymptomatic carriers of Neisseria meningitidis to eliminate Neisseria meningitidis in the nasopharynx; but it is not suitable for the treatment of Neisseria meningitidis infections.

Indication: (1) Isoniazid combined with other anti-tuberculosis drugs is suitable for the treatment of various types of tuberculosis, including tuberculous meningitis and other mycobacterial infections. (2) Isoniazid alone is suitable for the prevention of various types of tuberculosis: ① Family members or close contacts of patients recently diagnosed with tuberculosis; ② Patients with a strong positive tuberculin purified protein derivative test (PPD) and a chest X-ray examination consistent with non-progressive tuberculosis, negative sputum bacteria, and no formal anti-tuberculosis treatment in the past; ③ Patients who are receiving immunosuppressants or long-term hormone therapy, certain blood diseases or reticuloendothelial system diseases (such as leukemia, Hodgkin's disease), diabetes, uremia, silicosis or gastrectomy, whose PPD test is positive; ④ Patients under 35 years old with a positive PPD test; ⑤ People who are known or suspected to be infected with HIV, whose PPD test is positive, or who have close contact with patients with active pulmonary tuberculosis.

Indication: a) Isoniazid is used in combination with other anti-tuberculosis drugs for the treatment of various types of tuberculosis, including tuberculous meningitis and other mycobacterial infections. b) Isoniazid alone is suitable for the prevention of various types of tuberculosis: ① Family members or close contacts of patients recently diagnosed with tuberculosis ② Those with a strongly positive tuberculin purified protein derivative test (PPD) and a chest X-ray that is consistent with non-tuberculosis, negative sputum bacteria, and who have not received regular anti-tuberculosis treatment in the past ③ Patients who are receiving immunosuppressants or long-term hormone therapy, patients with certain blood diseases or reticuloendothelial system diseases (such as leukemia, Hodgkin's disease), diabetes, uremia, silicosis or gastrectomy, and whose PPD test is positive; ④ Those under 35 years old who have a positive PPD test ⑤ Those known or suspected to be infected with HIV, whose PPD test is positive, or those who have close contact with patients with active pulmonary tuberculosis.

Indication: 1. Isoniazid combined with other anti-tuberculosis drugs is suitable for the treatment of various types of tuberculosis, including tuberculous meningitis and other mycobacterial infections. 2. Isoniazid alone is suitable for the prevention of various types of tuberculosis: 1. Family members or close contacts of patients recently diagnosed with tuberculosis; 2. Patients with a strong positive tuberculin purified protein derivative test (PPD) and a chest X-ray examination consistent with non-progressive tuberculosis, negative sputum bacteria, and no formal anti-tuberculosis treatment in the past; 3. Patients who are receiving immunosuppressants or long-term hormone therapy, certain blood diseases or reticuloendothelial system diseases (such as leukemia, Hodgkin's disease), diabetes, uremia, silicosis or gastrectomy, whose tuberculin purified protein derivative test is positive; 4. Patients under 35 years old with a positive tuberculin purified protein derivative test; 5. People who are known or suspected to be infected with HIV, whose tuberculin purified protein derivative test is positive, or who have close contact with patients with active pulmonary tuberculosis.

Indication: 1. This product is used in combination with other anti-tuberculosis drugs for the initial and retreatment of various tuberculosis diseases, including the treatment of tuberculous meningitis. 2. This product is used in combination with other drugs to treat leprosy and non-tuberculous mycobacterial infections. 3. This product can be used in combination with vancomycin (intravenous) for severe infections caused by methicillin-resistant Staphylococci. The combination of rifampicin and erythromycin is used for severe Legionella infections. 4. It is used for asymptomatic carriers of Neisseria meningitidis to eliminate Neisseria meningitidis in the nasopharynx; but it is not suitable for the treatment of Neisseria meningitidis infections.

Indication: 1. This product is used in combination with other anti-tuberculosis drugs for the initial and retreatment of various tuberculosis diseases, including the treatment of tuberculous meningitis. 2. This product is used in combination with other drugs to treat leprosy and non-tuberculous mycobacterial infections. 3. This product can be used in combination with vancomycin (intravenous) for severe infections caused by methicillin-resistant Staphylococci. The combination of rifampicin and erythromycin is used for severe Legionella infections. 4. It is used for asymptomatic carriers of Neisseria meningitidis to eliminate Neisseria meningitidis in the nasopharynx; but it is not suitable for the treatment of Neisseria meningitidis infections.